GoAI
Get started
Senseonics Holdings, Inc. logo

Senseonics Holdings, Inc.

SENS

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$9.71

+$0.89 · +10.09%

Aug 21, 4:00 PM ET

SENS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

37

Expensive

Momentum

22

Weakening

Sentiment

63

Bullish

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Timothy T. Goodnow
Listed since
Dec 22, 2015
Employees
130

Market position

Day range

Current $9.71

52-week range

Current $9.71

Open
$9.60
Previous close
$8.82
Volume
1.28M
1.54× average
Average volume
833.06K
Average daily volume
Market cap
405.82M USD
Beta
0.97
Market reference 1
50-day average
$6.1527
+57.82% above average
200-day average
$6.5017
+49.35% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
231.16M USD
P/E (TTM)
-4.28×
P/B (TTM)
6.22×
P/S (TTM)
8.36×
EV / EBITDA
-3.69×
Earnings yield
-30.00%
Free cash flow yield
-26.15%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
54.87%
Operating margin
-223.22%
Net margin
-225.34%
Return on equity
-113.21%
Return on assets
-54.73%
Return on invested capital
-66.72%

Financial health

Debt / equity
0.68×
Current ratio
4.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1175%-57%-1288%-2520%Gross margin, FY2021: -5.93%Gross margin, FY2022: 16.63%Gross margin, FY2023: 13.81%Gross margin, FY2024: 2.37%Gross margin, FY2025: 44.71%Operating margin, FY2021: -418.15%Operating margin, FY2022: -418.74%Operating margin, FY2023: -337.66%Operating margin, FY2024: -333.05%Operating margin, FY2025: -193.83%Net margin, FY2021: -2211.88%Net margin, FY2022: 867.16%Net margin, FY2023: -269.73%Net margin, FY2024: -349.84%Net margin, FY2025: -196.03%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -5.93%. Gross margin FY2022 16.63%. Gross margin FY2023 13.81%. Gross margin FY2024 2.37%. Gross margin FY2025 44.71%. Operating margin FY2021 -418.15%. Operating margin FY2022 -418.74%. Operating margin FY2023 -337.66%. Operating margin FY2024 -333.05%. Operating margin FY2025 -193.83%. Net margin FY2021 -2211.88%. Net margin FY2022 867.16%. Net margin FY2023 -269.73%. Net margin FY2024 -349.84%. Net margin FY2025 -196.03%.

Income trends

Revenue

35.26M USD+56.89%

Operating income

−68.34M USD+8.69%

Net income

−69.11M USD+12.09%
Income trends across reported periods186.58M USD8.74M USD−169.1M USD−346.93M USDRevenue, FY2021: 13.68M USDRevenue, FY2022: 16.39M USDRevenue, FY2023: 22.39M USDRevenue, FY2024: 22.47M USDRevenue, FY2025: 35.26M USDOperating income, FY2021: −57.18M USDOperating income, FY2022: −68.63M USDOperating income, FY2023: −75.6M USDOperating income, FY2024: −74.84M USDOperating income, FY2025: −68.34M USDNet income, FY2021: −302.47M USDNet income, FY2022: 142.12M USDNet income, FY2023: −60.39M USDNet income, FY2024: −78.62M USDNet income, FY2025: −69.11M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.68M USD. Revenue FY2022 16.39M USD. Revenue FY2023 22.39M USD. Revenue FY2024 22.47M USD. Revenue FY2025 35.26M USD. Operating income FY2021 −57.18M USD. Operating income FY2022 −68.63M USD. Operating income FY2023 −75.6M USD. Operating income FY2024 −74.84M USD. Operating income FY2025 −68.34M USD. Net income FY2021 −302.47M USD. Net income FY2022 142.12M USD. Net income FY2023 −60.39M USD. Net income FY2024 −78.62M USD. Net income FY2025 −69.11M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue35.26M USD22.47M USD22.39M USD16.39M USD13.68M USD
Cost of goods sold19.49M USD21.94M USD19.3M USD13.66M USD14.49M USD
Gross profit15.76M USD533K USD3.09M USD2.73M USD−811K USD
Research and development31.59M USD41.14M USD48.75M USD39.72M USD27.22M USD
Selling, general, and administrative52.51M USD34.23M USD29.94M USD31.63M USD29.15M USD
Operating expenses84.1M USD75.38M USD78.69M USD71.35M USD56.37M USD
Interest income4.2M USD4.5M USD5.36M USD1.82M USD243K USD
Interest expense4.95M USD8.44M USD11.11M USD18.7M USD16.72M USD
Depreciation and amortization1.51M USD1.48M USD1.28M USD985K USD1.24M USD
Operating income−68.34M USD−74.84M USD−75.6M USD−68.63M USD−57.18M USD
Net income−69.11M USD−78.62M USD−60.39M USD142.12M USD−302.47M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
9%
1 beat, 6 misses, 4 met estimates
Average EPS surprise
-116.93%
11 comparable reports
Latest EPS result
-0.63
Estimate -0.61 · Miss by 2.84%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.27-0.52-0.76Q1 '25MissQ2 '25MetQ3 '25MetQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual -0.4, estimate -0.03, surprise -1233.33%, Miss. Q2 2025, reported May 8, 2025: actual -0.4, estimate -0.4, surprise 0.00%, Met estimate. Q3 2025, reported Aug 6, 2025: actual -0.4, estimate -0.4, surprise 0.00%, Met estimate. Q4 2025, reported Nov 5, 2025: actual -0.43, estimate -0.33, surprise -30.30%, Miss. Q1 2026, reported Mar 2, 2026: actual -0.46, estimate -0.43, surprise -6.98%, Miss. Q2 2026, reported May 7, 2026: actual -0.71, estimate -0.686, surprise -3.57%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.63, estimate -0.613, surprise -2.84%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.52, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates17.05M12.94M8.83M4.72MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 8.3M USD, estimate 7.95M USD, surprise +4.43%, Beat. Q2 2025, reported May 8, 2025: actual 6.26M USD, estimate 5.55M USD, surprise +12.72%, Beat. Q3 2025, reported Aug 6, 2025: actual 6.65M USD, estimate 6.02M USD, surprise +10.41%, Beat. Q4 2025, reported Nov 5, 2025: actual 8.1M USD, estimate 7.99M USD, surprise +1.34%, Beat. Q1 2026, reported Mar 2, 2026: actual 14.3M USD, estimate 14.24M USD, surprise +0.45%, Beat. Q2 2026, reported May 7, 2026: actual 11.71M USD, estimate 9.83M USD, surprise +19.15%, Beat. Q3 2026, reported Aug 6, 2026: actual 14.5M USD, estimate 13.35M USD, surprise +8.61%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 16.2M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

17 ratings
Strong buy00%
Buy953%
Hold529%
Sell318%
Strong sell00%

SENS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SENS

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.45M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
5.91M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
3.27M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.82M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
2M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.21M
Weight
0.08%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.12M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Core S&P Total U.S. Stock Market ETF logoiShares Core S&P Total U.S. Stock Market ETFITOT
Market value
454.86K
Weight
0.00%
AUM
97.17B USD
Expense ratio
0.03%
Price / 1D
$167.97+0.46%

Continue in GoAI

Research SENS

research.disclaimer